Systemic Hormones and Muscle Protein Synthesis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-15

Study Completion Date

2019-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the effect of increase in testosterone levels in older males and the effects of decrease in testosterone levels in young males on muscle protein synthesis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effects of Long Term Cyclic Testosterone Administration on Muscle Function and Bone in Older Men

NCT01417364

Sarcopenia

WITHDRAWN PHASE4

Dose-Response of Gonadal Steroids and Bone Turnover in Older Men

NCT00114114

Healthy Volunteers

COMPLETED NA

Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men

NCT00957801

Sarcopenia

COMPLETED PHASE4

Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men

NCT05773183

Hypogonadism, Male Testosterone Deficiency Prostate Cancer +8 more

UNKNOWN

Cycled Testosterone Replacement Study

NCT00957528

Hypogonadism

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Skeletal muscle represents the largest organ in the body, comprising \>50% of total body mass. The function of skeletal muscle is best understood for its role in locomotion and providing mechanical support to the skeleton to facilitate movement. However, skeletal muscles are also important for maintaining whole-body metabolic health. For example, muscles also act as a site for glucose disposal thereby acting to maintain whole-body glycaemic control. In addition, skeletal muscles represent a vast protein store, the amino acids from which can be used in times of fasting, infection and disease to provide energy to maintain other critical organs. Exercise (resistance type exercise (RE-T) in particular) still remains the most effective means by which to maintain and increase muscle mass through stimulation of muscle protein synthesis (MPS), despite this, how exercise regulates these changes in muscle mass is still unknown. A number of pathways have been inferred as key, however it is clear from a number of studies that systemic hormone levels, testosterone in particular, may provide a significant contribution. It is well known that chronic androgenic hormone deficiency can lead to a loss of lean body mass and strength, which can in turn contribute to impaired physical function. Furthermore, when testosterone levels are pharmacologically reduced (using a gonadotropin releasing hormone analogue) in healthy young males, resistance exercise training induced increases in muscle mass and strength are absent. Whilst systemic hormone levels are carefully maintained in youth (unless illness or deficiency is present), levels of these hormones decrease with age, particularly in those that are not regularly physically active, indeed approximately 25-30% of older men have levels of testosterone which are below the threshold used to define hypogonadism. Therefore, there is significant need to understand the underlying mechanisms behind hormonally induced muscle mass regulation. Furthermore, in older age there is a resistance to traditional anabolic stimuli such as nutrition or resistance exercise, with older adults showing a blunted-anabolic hormonal profile in response to resistance training compared to young. These impairments to hormonal regulation with ageing may in part be responsible for the slow decline in muscle mass with age known as sarcopenia. Whilst all muscle-wasting conditions are of considerable concern, it is the loss of muscle in older age that poses the greatest socio-economic burden. Therefore there is a significant clinical need to identify contributing factors to this muscle loss so that they can be specifically targeted for intervention (i.e., pharmacological hormonal therapies).

The aims of this project are two fold: 1) Firstly we aim to investigate the impact of systemic hormone levels on control of muscle mass in healthy young adults undertaking a resistance exercise training program, we hypothesize that reduction of hormone levels in systemically normal young adults will impair MPS and muscle mass gains in response to resistance exercise training. 2) Secondly we aim to investigate the impact of enhancing testosterone levels in older adults on responsiveness to resistance exercise training and the contribution of systemic testosterone levels to muscle mass regulation in ageing, we hypothesize that increasing testosterone levels in older males will improve responsiveness to anabolic stimuli (RE-T).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia Muscle Hypotrophy Muscle Atrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

To achieve our aims we will recruit 16 young healthy males (Age: 18-30 y; BMI: 18-30kg/m2) and 16 older healthy males (Age: 65-75 y; BMI: 18-30kg/m2). Volunteers will then be randomly assigned to a testing group; 1) Young placebo trained (N=10), 2) Young gonadotropin releasing hormone analogue trained (3.6mg Zoladex subcutaneous injection (every 4 weeks) N=10), 3) Old placebo trained (N=10) and 4) Old Testosterone trained (Sustanon 250: 250 mg every 2-3wks intramuscular injection, N=10). All participants will receive whole body resistance exercise training for six weeks.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Old Testosterone trained

8 old participants (65-75 years old) who will receive resistance exercise training and Testosterone (Sustanon 250: 250 mg every 2wks)

Drug name: Sustanon 250 Generic Name: Testosterone Proprietary Name: N/A Formulation: 250mg of Testosterone in 1ml volume Dose: 250mg of testosterone Frequency: every 2 weeks Route: intramuscular injection

Group Type EXPERIMENTAL

Sustanon 250

Intervention Type DRUG

The frequency of the injection will be every 2 weeks, 250mg of testosterone, intramuscular injection.

Old Placebo trained

8 old participants (65-75 years old) who will receive resistance exercise training and Placebo every two weeks.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Young Zoladex trained

8 young participants (18-30 years old) who will receive resistance exercise training and Testosterone inhibitor (3.6mg Zoladex subcutaneous injection, one time over the study)

Drug name: Zoladex Generic Name: Gonadotropin-releasing hormone analogue; Goserelin Proprietary Name: N/A Formulation: Solution for injection Dose: 3.6mg Frequency: Single injection one time over the study. Route: Subcutaneous injection (abdomen) performed by clinician.

Group Type EXPERIMENTAL

Zoladex

Intervention Type DRUG

The frequency of the injection will be just one injection, 3.6 mg of Zoladex, Subcutaneous injection (abdomen).

Young placebo trained

8 young participants (18-30 years old) who will receive resistance exercise training and placebo, one time over the study.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sustanon 250

The frequency of the injection will be every 2 weeks, 250mg of testosterone, intramuscular injection.

Intervention Type DRUG

Zoladex

The frequency of the injection will be just one injection, 3.6 mg of Zoladex, Subcutaneous injection (abdomen).

Intervention Type DRUG

Placebo

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Testosterone Gonadotropin-releasing hormone analogue; Goserelin Saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Young (18-30y) and old (60-75y) males who are generally healthy

Exclusion Criteria

* Participation in a formal exercise regime
* BMI \< 18 or \> 30 kg·m2
* Active cardiovascular disease:

* uncontrolled hypertension (BP \> 160/100),
* angina,
* heart failure (class III/IV),
* arrhythmia,
* right to left cardiac shunt,
* recent cardiac event
* Taking beta-adrenergic blocking agents, statins, non-steroidal anti-inflammatory drugs or HRT
* Cerebrovascular disease:

* previous stroke,
* aneurysm (large vessel or intracranial)
* epilepsy
* Respiratory disease including:

* pulmonary hypertension,
* COPD,
* asthma,
* Metabolic disease:

* hyper and hypo parathyroidism,
* Hypo and hyper gonadism
* untreated hyper and hypothyroidism,
* Cushing's disease,
* type 1 or 2 diabetes
* Active inflammatory bowel or renal disease
* Malignancy
* Altered hormonal profile
* Recent steroid treatment (within 6 months) or hormone replacement therapy
* Clotting dysfunction
* Musculoskeletal or neurological disorders
* Family history of early (\<55y) death from cardiovascular disease

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes